Specific targeting of nasopharyngeal carcinoma cell line CNE1 by C225-conjugated ultrasmall superparamagnetic iron oxide particles with magnetic resonance imaging

Acta Biochimica et Biophysica Sinica

Volumn 43, Issue 4, 2011, Pages 301-306

  Liu, Dongbo ^a   Chen, Chunli ^a   Hu, Guangyuan ^a   Mei, Qi ^a   Qiu, Hong ^a   Long, Guoxian ^a   Hu, Guoqing ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

cetuximab; epidermal growth factor receptor; magnetic resonance imaging; ultrasmall superparamagnetic iron oxide

Indexed keywords

ANTINEOPLASTIC AGENT; CETUXIMAB; CONTRAST MEDIUM; DEXTRAN; EPIDERMAL GROWTH FACTOR RECEPTOR; FERRIC ION; FERRIC OXIDE; FERUMOXTRAN 10; FERUMOXTRAN-10; MAGNETITE NANOPARTICLE; MONOCLONAL ANTIBODY;

ARTICLE; CHEMISTRY; DRUG ANTAGONISM; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; HUMAN; IMMUNOLOGY; METABOLISM; METHODOLOGY; NASOPHARYNX CARCINOMA; NASOPHARYNX TUMOR; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; TRANSMISSION ELECTRON MICROSCOPY; TUMOR CELL LINE; ULTRASTRUCTURE; WESTERN BLOTTING;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; CELL LINE, TUMOR; CONTRAST MEDIA; DEXTRANS; FERRIC COMPOUNDS; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; MAGNETIC RESONANCE IMAGING; MAGNETITE NANOPARTICLES; MICROSCOPY, ELECTRON, TRANSMISSION; NASOPHARYNGEAL NEOPLASMS; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 79953176704     PISSN: 16729145     EISSN: 17457270     Source Type: Journal    
DOI: 10.1093/abbs/gmr010     Document Type: Article

References (30)

1. Yu MC and Yuan JM. Epidemiology of nasopharyngeal carcinoma. Semin Cancer Biol 2002, 12: 421-429. (Pubitemid 35370755)
2. Lee AW, Sze WM, Au JS, Leung SF, Leung TW, Chua DT and Zee BC, et al. Treatment results for nasopharyngeal carcinoma in the modern era: the Hong Kong experience. Int J Radiat Oncol Biol Phys 2005, 61: 1107-1116. (Pubitemid 40340904)
3. Ng SH, Chang TC, Ko SF, Yen PS, Wan YL, Tang LM and Tsai MH. Nasopharyngeal carcinoma: MRI and CT assessment. Neuroradiology 1997, 39: 741-746. (Pubitemid 27425071)
4. Liao XB, Mao YP, Liu LZ, Tang LL, Sun Y, Wang Y and Lin AH, et al. How does magnetic resonance imaging influence staging according to AJCC staging system for nasopharyngeal carcinoma compared with computed tomography? Int J Radiat Oncol Biol Phys 2008, 72: 1368-1377.
5. Comoretto M, Balestreri L, Borsatti E, Cimitan M, Franchin G and Lise M. Detection and restaging of residual and/or recurrent nasopharyngeal carcinoma after chemotherapy and radiation therapy: comparison of MR imaging and FDG PET/CT. Radiology 2008, 249: 203-211.
6. Varallyay P, Nesbit G, Muldnoon LL, Nixon RR, Delashaw J, Cohen JI and Petrillo A, et al. Comparison of two superparamagnetic viral-sized iron oxide particles ferumoxides and ferumoxtran-10 with a gadolinium chelate in imaging intracranial tumors. AJNR Am J Neuroradiol 2002, 23: 510-519. (Pubitemid 34411901)
7. Anzai Y, Piccoli CW, Outwater EK, Stanford W, Bluemke DA, Nurenberg P and Saini S, et al. Evaluation of neck and body metastases to nodes with ferumoxtran 10-enhanced MR imaging: phase III safety and efficacy study. Radiology 2003, 228: 777-788. (Pubitemid 37025489)
8. Will O, Purkayastha S, Chan C, Athanasiou T, Darzi AW, Gedroyc W and Tekkis PP. Diagnostic precision of nanoparticle-enhanced MRI for lymphnode metastases: a meta-analysis. Lancet Oncol 2006, 7: 52-60. (Pubitemid 43025393)
9. Heesakkers RA, Hövels AM, Jager GJ, van den Bosch HC, Witjes JA, Raat HP and Severens JL, et al. MRI with a lymph-node-specific contrast agent as an alternative to CT scan and lymph-node dissection in patients with prostate cancer: a prospective multicohort study. Lancet Oncol 2008, 9: 850-856.
10. Lahaye MJ, Engelen SM, Kessels AG, de Bruïne AP, von Meyenfeldt MF, van Engelshoven JM and van de Velde CJ, et al. USPIO-enhanced MR imaging for nodal staging in patients with primary rectal cancer: predictive criteria. Radiology 2008, 246: 804-811.
11. Rockall AG, Sohaib SA, Harisinghani MG, Babar SA, Singh N, Jeyarajah AR and Oram DH, et al. Diagnostic performance of nanoparticle-enhanced magnetic resonance imaging in the diagnosis of lymph node metastases in patients with endometrial and cervical cancer. J Clin Oncol 2005, 23: 2813-2821. (Pubitemid 46179472)
12. Li X, Du X, Huo T, Liu X, Zhang S and Yuan F. Specific targeting of breast tumor by octreotide-conjugated ultrasmall superparamagnetic iron oxide particles using a clinical 3.0-Tesla magnetic resonance scanner. Acta Radiol 2009, 50: 583-594.
13. 3-integrin-expressing glioma cells and only accumulates in the vascular tumor compartment. Radiology 2009, 253: 462-469.
14. Baio G, Fabbi M, Salvi S, de Totero D, Truini M, Ferrini S and Neumaier CE. Two-step in vivo tumor targeting by biotin-conjugated antibodies and superparamagnetic nanoparticles assessed by magnetic resonance imaging at 1.5 T. Mol Imaging Biol 2010, 12: 305-315.
15. Huh YM, Jun YW, Song HT, Kim S, Choi JS, Lee JH and Yoon S, et al. In vivo magnetic resonance detection of cancer by using multifunctional magnetic nanocrystals. J Am Chem Soc 2005, 127: 12378-12391.
16. Kou G, Wang S, Cheng C, Gao J, Li B, Wang H and Qian W, et al. Development of SM5-1-conjugated ultrasmall superparamagnetic iron oxide nanoparticles for hepatoma detection. Biochem Biophys Res Commun 2008, 374: 192-197.
17. Vermorken JB, Mesia R, Rivera F, Remenar E, Kawecki A, Rottey S and Erfan J, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 2008, 359: 1116-1127.
18. Van Cutsem E, Köhne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A and D'Haens G, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009, 360: 1408-1417.
19. Pirker R, Pereira JR, Szczesna A, von Pawel J, Krzakowski M, Ramlau R and Vynnychenko I, et al. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet 2009, 373: 1525-1531.
20. Ma BB, Poon TC, To KF, Zee B, Mo FK, Chan CM and Ho S, et al. Prognostic significance of tumor angiogenesis, Ki67, p53 oncoprotein, epidermal growth factor receptor and HER2 receptor protein expression in undifferentiated nasopharyngeal carcinoma - a prospective study. Head Neck 2003, 25: 864-872. (Pubitemid 37139899)
21. Taheri-Kadkhoda Z, Magnusson B, Svensson M, Mercke C and Björk-Eriksson T. Expression modes and clinical manifestations of latent membrane protein 1, Ki-67, cyclin-B1, and epidermal growth factor receptor in nonendemic nasopharyngeal carcinoma. Head Neck 2009, 31: 482-492.
22. Leong JL, Loh KS, Putti TC, Goh BC and Tan LK. Epidermal growth factor receptor in undifferentiated carcinoma of the nasopharynx. Laryngoscope 2004, 114: 153-157. (Pubitemid 38141085)
23. Wolden SL, Chen WC, Pfister DG, Kraus DH, Berry SL and Zelefsky MJ. Intensity-modulated radiation therapy (IMRT) for nasopharynx cancer: update of the Memorial Sloan-Kettering experience. Int J Radiat Oncol Biol Phys 2006, 64: 57-62. (Pubitemid 41831209)
24. Sun EY, Josephson L, Kelly KA and Weissleder R. Development of nano- particle libraries for biosensing. Bioconjug Chem 2006, 17: 109-113.
25. Cerdan S, Lötscher HR, Künnecke B and Seeling J. Monoclonal antibody- coated magnetite particles as contrast agents in magnetic resonance imaging of tumors. Magn Reson Med 1989, 12: 151-163. (Pubitemid 19271503)
26. Remsen LG, McCormick CI, Roman-Goldstein S, Nilaver G, Weissleder R, Bogdanov A and Hellström I, et al. MR of carcinoma-specific monoclonal antibody conjugated to monocrystalline iron oxide nanoparticles: the potential for noninvasive diagnosis. AJNR Am J Neuroradiol 1996, 17: 411-418. (Pubitemid 26101942)
27. Suwa T, Ozawa S, Ueda M, Ando N and Kitajima M. Magnetic resonance imaging of esophageal squamous cell carcinoma using magnetite particles coated with anti-epidermal growth factor receptor antibody. Int J Cancer 1998, 75: 626-634. (Pubitemid 28094112)
28. Reynolds PR, Larkman DJ, Haskard DO, Hajnal JV, Kennea NL, George AJ and Edwards AD. Detection of vascular expression of E-selectin in vivo with MR imaging. Radiology 2006, 241: 469-476. (Pubitemid 44632893)
29. Raynal I, Prigent P, Peyramaure S, Najid A, Rebuzzi C and Corot C. Macrophage endocytosis of superparamagnetic iron oxide nanoparticles: mechanisms and comparison of ferumoxides and ferumoxtran-10. Invest Radiol 2004, 39: 56-63. (Pubitemid 38030177)
30. Fleige G, Seeberger F, Laux D, Kresse M, Taupitz M, Pilgrimm H and Zimmer C. In vitro characterization of two different ultrasmall iron oxide particles for magnetic resonance cell tracking. Invest Radiol 2002, 37: 482-488. (Pubitemid 34966853)